Investor's Business Daily on MSN2mon
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
Regeneron announced Friday that the company won Food and Drug Administration approval for Dupixent in chronic obstructive ...
Dupixent® (Dupilumab) Sbla Accepted For FDA Review For The Treatment Of Chronic Spontaneous Urticaria (CSU)
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity M ...
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...